These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
230 related articles for article (PubMed ID: 12952295)
1. Immunogene therapy of recurrent glioblastoma multiforme with a liposomally encapsulated replication-incompetent Semliki forest virus vector carrying the human interleukin-12 gene--a phase I/II clinical protocol. Ren H; Boulikas T; Lundstrom K; Söling A; Warnke PC; Rainov NG J Neurooncol; 2003; 64(1-2):147-54. PubMed ID: 12952295 [TBL] [Abstract][Full Text] [Related]
2. Transfer of the murine interleukin-12 gene in vivo by a Semliki Forest virus vector induces B16 tumor regression through inhibition of tumor blood vessel formation monitored by Doppler ultrasonography. Asselin-Paturel C; Lassau N; Guinebretière JM; Zhang J; Gay F; Bex F; Hallez S; Leclere J; Peronneau P; Mami-Chouaib F; Chouaib S Gene Ther; 1999 Apr; 6(4):606-15. PubMed ID: 10476220 [TBL] [Abstract][Full Text] [Related]
3. Induction of a therapeutic antitumor immunological response by intratumoral injection of genetically engineered Semliki Forest virus to produce interleukin-12. Yamanaka R; Zullo SA; Tanaka R; Ramsey J; Blaese M; Xanthopoulos KG Neurosurg Focus; 2000 Dec; 9(6):e7. PubMed ID: 16817690 [TBL] [Abstract][Full Text] [Related]
4. Induction of an antitumor immunological response by an intratumoral injection of dendritic cells pulsed with genetically engineered Semliki Forest virus to produce interleukin-18 combined with the systemic administration of interleukin-12. Yamanaka R; Tsuchiya N; Yajima N; Honma J; Hasegawa H; Tanaka R; Ramsey J; Blaese RM; Xanthopoulos KG J Neurosurg; 2003 Oct; 99(4):746-53. PubMed ID: 14567611 [TBL] [Abstract][Full Text] [Related]
5. Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma. Patel DM; Foreman PM; Nabors LB; Riley KO; Gillespie GY; Markert JM Hum Gene Ther Clin Dev; 2016 Jun; 27(2):69-78. PubMed ID: 27314913 [TBL] [Abstract][Full Text] [Related]
6. Marked enhancement of antitumor immune responses in mouse brain tumor models by genetically modified dendritic cells producing Semliki Forest virus-mediated interleukin-12. Yamanaka R; Zullo SA; Ramsey J; Yajima N; Tsuchiya N; Tanaka R; Blaese M; Xanthopoulos KG J Neurosurg; 2002 Sep; 97(3):611-8. PubMed ID: 12296646 [TBL] [Abstract][Full Text] [Related]
7. Regression of mouse tumours and inhibition of metastases following administration of a Semliki Forest virus vector with enhanced expression of IL-12. Chikkanna-Gowda CP; Sheahan BJ; Fleeton MN; Atkins GJ Gene Ther; 2005 Aug; 12(16):1253-63. PubMed ID: 15944731 [TBL] [Abstract][Full Text] [Related]
8. Virotherapy with a Semliki Forest Virus-Based Vector Encoding IL12 Synergizes with PD-1/PD-L1 Blockade. Quetglas JI; Labiano S; Aznar MÁ; Bolaños E; Azpilikueta A; Rodriguez I; Casales E; Sánchez-Paulete AR; Segura V; Smerdou C; Melero I Cancer Immunol Res; 2015 May; 3(5):449-54. PubMed ID: 25691326 [TBL] [Abstract][Full Text] [Related]
9. Administration of interleukin-12 and -18 enhancing the antitumor immunity of genetically modified dendritic cells that had been pulsed with Semliki forest virus-mediated tumor complementary DNA. Yamanaka R; Yajima N; Tsuchiya N; Honma J; Tanaka R; Ramsey J; Blaese M; Xanthopoulos KG J Neurosurg; 2002 Nov; 97(5):1184-90. PubMed ID: 12450042 [TBL] [Abstract][Full Text] [Related]
10. Short-term intratumoral interleukin-12 expressed from an alphaviral vector is sufficient to induce an efficient antitumoral response against spontaneous hepatocellular carcinomas. Rodriguez-Madoz JR; Zabala M; Alfaro M; Prieto J; Kramer MG; Smerdou C Hum Gene Ther; 2014 Feb; 25(2):132-43. PubMed ID: 24219025 [TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant administration of Semliki Forest virus expressing interleukin-12 combined with attenuated Salmonella eradicates breast cancer metastasis and achieves long-term survival in immunocompetent mice. Kramer MG; Masner M; Casales E; Moreno M; Smerdou C; Chabalgoity JA BMC Cancer; 2015 Sep; 15():620. PubMed ID: 26347489 [TBL] [Abstract][Full Text] [Related]
12. Cloning of human IL-12 p40 and p35 DNA into the Semliki Forest virus vector: expression of IL-12 in human tumor cells. Zhang J; Asselin-Paturel C; Bex F; Bernard J; Chehimi J; Willems F; Caignard A; Berglund P; Liljeström P; Burny A; Chouaib S Gene Ther; 1997 Apr; 4(4):367-74. PubMed ID: 9176524 [TBL] [Abstract][Full Text] [Related]
13. Augmentation of alphavirus vector-induced human papilloma virus-specific immune and anti-tumour responses by co-expression of interleukin-12. Riezebos-Brilman A; Regts J; Chen M; Wilschut J; Daemen T Vaccine; 2009 Jan; 27(5):701-7. PubMed ID: 19041356 [TBL] [Abstract][Full Text] [Related]
15. MicroRNA-Attenuated Clone of Virulent Semliki Forest Virus Overcomes Antiviral Type I Interferon in Resistant Mouse CT-2A Glioma. Martikainen M; Niittykoski M; von und zu Fraunberg M; Immonen A; Koponen S; van Geenen M; Vähä-Koskela M; Ylösmäki E; Jääskeläinen JE; Saksela K; Hinkkanen A J Virol; 2015 Oct; 89(20):10637-47. PubMed ID: 26269187 [TBL] [Abstract][Full Text] [Related]